ATRA Stock Analysis: Buy, Sell, or Hold?
ATRA - Atara Biotherapeutics, Inc
$10.55
-0.61 (-5.47%)
▼
5d:
+9.67%
30d:
+7.65%
90d:
+111.42%
BUY
MODERATE Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When ATRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ATRA shows positive signals but monitor for confirmation. Market pricing in 21.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ATRA shows positive signals but monitor for confirmation. Market pricing in 21.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$30.79
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$19.12
44.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ATRA is currently trading at $10.55, which is considered slightly high relative to its 30-day fair value range of $9.50 to $10.56. From a valuation perspective, the stock is trading at a discount (Forward PE: 8.3) compared to its historical average (17.3). Remarkably, the market is currently pricing in an annual earnings decline of 21.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ATRA is in a strong uptrend. Immediate support is located at $9.21, while resistance sits at $11.55. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.67 (+29.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATRA is in a strong uptrend. Immediate support is located at $9.21, while resistance sits at $11.55. Short-term momentum is weak, with the stock down 5.5% recently.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.67 (+29.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$9.50 -
$10.56
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
60.5%
All Signals
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.5%)
- BULLISH: Trading 29.5% below Wall St target ($13.67)
Trading Range Analysis
30-Day Trading Range
$9.50 -
$10.56
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.21
Resistance Level
$11.55
Current Trend
Strong Uptrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.31
Wall Street Target
$13.67
(+29.5%)
Revenue Growth (YoY)
-99.5%
Profit Margin
-40.9%
Valuation Discount vs History
-21.8% cheaper
PE vs Historical
8.3 vs 17.3
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-21.8%
(market-implied from PE analysis)
1-Year Target
$9.50
(-10%)
2-Year Target
$8.55
(-19%)
3-Year Target
$7.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 8→17)
$16.02
(+52%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.3 to 17.3
Stabilization Target:
$21.97
(+108.3%)
PE Expansion Potential:
+108.3%
Share & Embed Analysis
Last updated: June 24, 2026 6:55 PM ET
Data refreshes hourly during market hours. Next update: 7:55 PM
Data refreshes hourly during market hours. Next update: 7:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Innovation Ltd Panacea
SELL
80554 shares
2026-01-12
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 61 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 58 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 58 HOLD |
